Literature DB >> 30835030

HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.

Thomas J Vogl1, Tatjana Gruber-Rouh2.   

Abstract

With the increasing incidence of hepatocellular carcinoma (HCC) and its high mortality rates, effective treatment options are of urgent need, preferably in a multidisciplinary setting. In the management of those patients, interventional radiologists play a key role. In this article, we reviewed the current literature for regional, intraarterial treatment strategies of advanced-stage HCC including conventional transarterial chemoembolization, transarterial embolization, transarterial embolization with drug-eluting beads, and selective internal radiation therapy.

Entities:  

Keywords:  Conventional transarterial chemoembolization (cTACE); Drugeluting bead TACE (DEB-TACE); Hepatocellular carcinoma (HCC); Selective internal radiation therapy (SIRT)

Mesh:

Year:  2019        PMID: 30835030     DOI: 10.1007/s10620-019-05542-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  63 in total

Review 1.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

2.  [Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].

Authors:  Tao Chen; Zhong-Hua Chu; Jian-Ping Liu; Jie Wang; Hai-Yan Zhao; Qing-Jia Ou
Journal:  Ai Zheng       Date:  2005-08

3.  Lipiodol transarterial chemoembolization for hepatocellular carcinoma: Where are we now?

Authors:  Franco Trevisani; Rita Golfieri
Journal:  Hepatology       Date:  2016-04-15       Impact factor: 17.425

Review 4.  Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.

Authors:  Letiția Adela Maria Streba; Cristin Constantin Vere; Ion Rogoveanu; Costin Teodor Streba
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

5.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

Authors:  María Varela; María Isabel Real; Marta Burrel; Alejandro Forner; Margarita Sala; Mercé Brunet; Carmen Ayuso; Lluis Castells; Xavier Montañá; Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2006-11-29       Impact factor: 25.083

6.  Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period.

Authors:  Tatjana Gruber-Rouh; Nagy N N Naguib; Katrin Eichler; Hanns Ackermann; Stephan Zangos; Jörg Trojan; Martin Beeres; Marc Harth; Boris Schulz; Nour-Eldin Nour-Eldin A; Thomas J Vogl
Journal:  Int J Cancer       Date:  2013-09-03       Impact factor: 7.396

7.  Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.

Authors:  S Grozinsky-Glasberg; G Kaltsas; M Kaltsatou; N Lev-Cohain; A Klimov; V Vergadis; I Uri; A I Bloom; D J Gross
Journal:  Endocrine       Date:  2018-01-30       Impact factor: 3.633

8.  Transarterial Chemoembolization (TACE) Using Mitomycin with or without Irinotecan for Hepatocellular Carcinoma in European Patients.

Authors:  Tatjana Gruber-Rouh; Ahmed Kamal; Katrin Eichler; Nagy N Naguib; Martin Beeres; Marcel Langenbach; Thomas J Vogl
Journal:  Oncol Res Treat       Date:  2018-07-16       Impact factor: 2.825

9.  Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis.

Authors:  Yuko Takeba; Toshio Kumai; Naoki Matsumoto; Sachiko Nakaya; Yoshimitsu Tsuzuki; Yohei Yanagida; Shinichi Kobayashi
Journal:  J Pharmacol Sci       Date:  2007-07-03       Impact factor: 3.337

10.  Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.

Authors:  Jodie Chang; Resmi Charalel; Christopher Noda; Raja Ramaswamy; Seung Kwon Kim; Michael Darcy; Gretchen Foltz; Olaguoke Akinwande
Journal:  Anticancer Res       Date:  2018-05       Impact factor: 2.480

View more
  5 in total

1.  Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma.

Authors:  Irvin Rexha; Fabian Laage-Gaupp; Julius Chapiro; Milena Anna Miszczuk; Johanna Maria Mijntje van Breugel; MingDe Lin; Menelaos Konstantinidis; Rafael Duran; Bernhard Gebauer; Christos Georgiades; Kelvin Hong; Nariman Nezami
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

Review 2.  Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors.

Authors:  Yasushi Kimura; Mario Ghosn; Waseem Cheema; Prasad S Adusumilli; Stephen B Solomon; Govindarajan Srimathveeralli
Journal:  Mol Ther Oncolytics       Date:  2021-12-21       Impact factor: 7.200

3.  Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T).

Authors:  Yi-Sheng Liu; Pi-Yi Chang; Po-Chin Liang; Ming-Ching Ou; Jen-I Hwang; Chien-Hung Chen
Journal:  J Hepatocell Carcinoma       Date:  2022-08-15

4.  Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma.

Authors:  Marie Vogeler; Isabelle Mohr; Jan Pfeiffenberger; Simon David Sprengel; Miriam Klauss; Boris Radeleff; Andreas Teufel; De-Hua Chang; Christoph Springfeld; Thomas Longerich; Uta Merle; Arianeb Mehrabi; Karl Heinz Weiss; Markus Mieth
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-25       Impact factor: 4.322

Review 5.  Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?

Authors:  Evgenia Kotsifa; Chrysovalantis Vergadis; Michael Vailas; Nikolaos Machairas; Stylianos Kykalos; Christos Damaskos; Nikolaos Garmpis; Georgios D Lianos; Dimitrios Schizas
Journal:  J Pers Med       Date:  2022-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.